Bausch And Lomb Drug Patent Portfolio
Bausch And Lomb owns 9 orange book drugs protected by 31 US patents with Miochol-E having the least patent protection, holding only 1 patent. And Prolensa with maximum patent protection, holding 9 patents. Given below is the list of Bausch And Lomb's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9517220 | Bromfenac bioavailability | 11 Nov, 2033 | Active |
| US10085958 | Bromfenac bioavailability | 19 Nov, 2032 | Active |
| US8481526 | Fluoroquinolone carboxylic acid molecular crystals | 09 Jan, 2031 | Active |
| US8415342 | Besifloxacin ophthalmic composition for the treatment or control of infection | 07 Nov, 2030 | Active |
| US8604020 | Fluoroquinolone carboxylic acid molecular crystals | 12 Mar, 2030 | Active |
| US8937062 | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria | 13 Nov, 2029 | Active |
| US8058467 | Prostaglandin derivatives | 21 Feb, 2029 | Active |
| US7273946 | Prostaglandin derivatives | 03 Oct, 2025 | Active |
| US8129431 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 11 Sep, 2025 | Active |
| US7629345 | Prostaglandin derivatives | 05 Jan, 2025 | Active |
| US7910767 | Prostaglandin derivatives | 05 Jan, 2025 | Active |
| US8669290 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 16 Jan, 2024 | Expired |
| US8754131 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 16 Jan, 2024 | Expired |
| US8871813 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 16 Jan, 2024 | Expired |
| US8927606 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 16 Jan, 2024 | Expired |
| US9144609 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 16 Jan, 2024 | Expired |
| US9561277 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | 16 Jan, 2024 | Expired |
| US6685958 | Quinolone carboxylic acid compositions and related methods of treatment | 29 Jun, 2021 | Expired |
| US6261546 | Methods and compositions for stabilizing acetylcholine compositions | 29 Apr, 2019 | Expired |
| US6699492 | Quinolone carboxylic acid compositions and related methods of treatment | 31 Mar, 2019 | Expired |
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | 22 Mar, 2019 | Expired |
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | 22 Mar, 2019 | Expired |
| US6645963 | Prolonged-action eye drop | 16 Nov, 2018 | Expired |
| US6335335 | Prolonged-action eye drop | 02 Nov, 2018 | Expired |
| US6211233 | Prostaglandin pharmaceutical compositions | 17 Jun, 2018 | Expired |
| US5447926 | Quinolone carboxylic acid derivatives | 13 Apr, 2016 | Expired |
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment | 25 Apr, 2014 | Expired |
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment | 25 Apr, 2014 | Expired |
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment | 25 Oct, 2013 | Expired |
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment | 25 Oct, 2013 | Expired |
| US4996335 | Soft steroids having anti-inflammatory activity | 09 Sep, 2012 | Expired |
Latest Legal Activities on Bausch And Lomb's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bausch And Lomb.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9517220 |
|
Patent Term Extension Certificate
Critical
| 18 Mar, 2024 | US8058467 |
|
Withdrawal of Application for PTE
Critical
| 18 Mar, 2024 | US7629345 |
|
Withdrawal of Application for PTE
Critical
| 18 Mar, 2024 | US7273946 |
| Notice of Final Determination -Election Required | 13 Feb, 2024 | US8058467 |
| Notice of Final Determination -Election Required | 13 Feb, 2024 | US7273946 |
| Notice of Final Determination -Election Required | 13 Feb, 2024 | US7629345 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US7629345 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US8058467 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US7273946 |
| Requirement for information sent under 37 CFR 1.750 | 26 Jan, 2024 | US7629345 |
| Requirement for information sent under 37 CFR 1.750 | 26 Jan, 2024 | US7273946 |
| Requirement for information sent under 37 CFR 1.750 | 26 Jan, 2024 | US8058467 |
|
FDA Final Eligibility Letter
Critical
| 14 Nov, 2023 | US7629345 |
| transaction for FDA Determination of Regulatory Review Period | 04 May, 2023 | US7273946 |
Bausch And Lomb's Drug Patent Litigations
Bausch And Lomb's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 26, 2014, against patent number US8669290. The petitioner Metrics, Inc., challenged the validity of this patent, with SENJU PHARMACEUTICAL CO., LTD. as the respondent. Click below to track the latest information on how companies are challenging Bausch And Lomb's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8669290 | April, 2015 |
FWD Entered
(12 Sep, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8754131 | April, 2015 |
FWD Entered
(12 Sep, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8754131 | November, 2015 |
FWD Entered
(12 Sep, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8871813 | April, 2015 |
FWD Entered
(12 Sep, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8871813 | November, 2015 |
FWD Entered
(12 Sep, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8927606 | April, 2015 |
FWD Entered
(12 Sep, 2016)
| Senju Pharmaceutical Co., Ltd. | Lupin Ltd. |
| US8927606 | November, 2015 |
FWD Entered
(12 Sep, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8129431 | September, 2015 |
FWD Entered
(05 Aug, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8129431 | March, 2015 |
FWD Entered
(28 Jul, 2016)
| Senju Pharmaceutical Co., Ltd. | InnoPharma, Licensing, Inc. |
| US8669290 | March, 2015 |
FWD Entered
(28 Jul, 2016)
| SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8129431 | June, 2014 |
Terminated-Settled
(08 Jul, 2015)
| Senju Pharmaceutical Co., Ltd. | Metrics, Inc. c/o Duane Morris LLP |
| US8669290 | June, 2014 |
Terminated-Settled
(08 Jul, 2015)
| SENJU PHARMACEUTICAL CO., LTD. | Metrics, Inc. |
Bausch And Lomb Drug Patents' Oppositions Filed in EPO
Bausch And Lomb drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 30, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04702854A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP04804405A | Nov, 2016 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP04702854A | Jan, 2009 | Teva Pharmaceutical Industries Ltd. | Opposition procedure closed |
Bausch And Lomb's Family Patents
Bausch And Lomb Drug List
Given below is the complete list of Bausch And Lomb's drugs and the patents protecting them.
1. Alrex
Alrex is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5540930
(Pediatric)
| Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Apr, 2014
(10 years ago)
| Expired |
| US5747061
(Pediatric)
| Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Apr, 2014
(10 years ago)
| Expired |
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Oct, 2013
(11 years ago)
| Expired |
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Oct, 2013
(11 years ago)
| Expired |
| US4996335
(Pediatric)
| Soft steroids having anti-inflammatory activity |
09 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alrex's drug page
2. Besivance
Besivance is protected by 7 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8481526 | Fluoroquinolone carboxylic acid molecular crystals |
09 Jan, 2031
(6 years from now)
| Active |
| US8415342 | Besifloxacin ophthalmic composition for the treatment or control of infection |
07 Nov, 2030
(5 years from now)
| Active |
| US8604020 | Fluoroquinolone carboxylic acid molecular crystals |
12 Mar, 2030
(5 years from now)
| Active |
| US8937062 | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
13 Nov, 2029
(4 years from now)
| Active |
| US6685958 | Quinolone carboxylic acid compositions and related methods of treatment |
29 Jun, 2021
(3 years ago)
| Expired |
| US6699492 | Quinolone carboxylic acid compositions and related methods of treatment |
31 Mar, 2019
(5 years ago)
| Expired |
| US5447926 | Quinolone carboxylic acid derivatives |
13 Apr, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Besivance's drug page
3. Istalol
Istalol is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6645963 | Prolonged-action eye drop |
16 Nov, 2018
(6 years ago)
| Expired |
| US6335335 | Prolonged-action eye drop |
02 Nov, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Istalol's drug page
4. Lotemax
Lotemax is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5540930
(Pediatric)
| Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Apr, 2014
(10 years ago)
| Expired |
| US5747061
(Pediatric)
| Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Apr, 2014
(10 years ago)
| Expired |
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Oct, 2013
(11 years ago)
| Expired |
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Oct, 2013
(11 years ago)
| Expired |
| US4996335
(Pediatric)
| Soft steroids having anti-inflammatory activity |
09 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotemax's drug page
5. Miochol-e
Miochol-e is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6261546 | Methods and compositions for stabilizing acetylcholine compositions |
29 Apr, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Miochol-e's drug page
Explore Our Curated Drug Screens
6. Prolensa
Prolensa is protected by 9 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9517220 | Bromfenac bioavailability |
11 Nov, 2033
(8 years from now)
| Active |
| US10085958 | Bromfenac bioavailability |
19 Nov, 2032
(7 years from now)
| Active |
| US8129431 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
11 Sep, 2025
(8 months from now)
| Active |
| US8669290 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
16 Jan, 2024
(11 months ago)
| Expired |
| US8754131 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
16 Jan, 2024
(11 months ago)
| Expired |
| US8871813 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
16 Jan, 2024
(11 months ago)
| Expired |
| US8927606 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
16 Jan, 2024
(11 months ago)
| Expired |
| US9144609 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
16 Jan, 2024
(11 months ago)
| Expired |
| US9561277 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
16 Jan, 2024
(11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prolensa's drug page
7. Retisert
Retisert is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
22 Mar, 2019
(5 years ago)
| Expired |
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
22 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retisert's drug page
8. Vyzulta
Vyzulta is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8058467 | Prostaglandin derivatives |
21 Feb, 2029
(4 years from now)
| Active |
| US7273946 | Prostaglandin derivatives |
03 Oct, 2025
(9 months from now)
| Active |
| US7629345 | Prostaglandin derivatives |
05 Jan, 2025
(17 days from now)
| Active |
| US7910767 | Prostaglandin derivatives |
05 Jan, 2025
(17 days from now)
| Active |
| US6211233 | Prostaglandin pharmaceutical compositions |
17 Jun, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyzulta's drug page
9. Zylet
Zylet is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5540930
(Pediatric)
| Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Apr, 2014
(10 years ago)
| Expired |
| US5747061
(Pediatric)
| Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Apr, 2014
(10 years ago)
| Expired |
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Oct, 2013
(11 years ago)
| Expired |
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
25 Oct, 2013
(11 years ago)
| Expired |
| US4996335
(Pediatric)
| Soft steroids having anti-inflammatory activity |
09 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zylet's drug page